The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V status according to the Office of the Federal Register.
The developer of the pharmaceutical, GW Pharma (NASDAQ: GWPH), had suggested previously that it expected to receive Schedule IV or better, so the outcome was favorable. Schedule V, according to the DEA:
Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
GW Pharma stock posted an all-time high last week in advance of the finalization of its approval, as the DEA was required to provide a scheduling within 90 days of FDA approval.
The company, which owns the global rights to Epidiolex, has stated that it will begin sales immediately upon scheduling.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.